B+
Bull case
25%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
AMLX
AmylyxDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$17.00
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-04-29 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-04-29
Recent news sentiment (30D)
+95.0
Positive
Company
+95.0
Positive
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+3.2
Score
AI commentary
Primary-source evidence is solid, but the current setup still looks like a cautious monitoring story rather than a broad fundamental inflection: recent headlines are pipeline-progress oriented, not revenue-driven, deterministic priors are negative across 5d to 120d, and there is no strong secondary evidence here of broad post-filing estimate upgrades or expanding coverage. Headline buzz is moderate because of the March enrollment update, but conviction should stay restrained until the Q3 2026 avexitide readout clarifies whether the main catalyst is value-creating or value-destructive.
RankAlpha Sentiment Codex - 2026-04-29
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-30eventAvexitide Phase 3 LUCIDITY topline data in Q3 2026High impact
Management's March 2026 materials say Phase 3 LUCIDITY enrollment is complete, topline avexitide data are expected in Q3 2026, and a successful readout would be the clearest near-term re-rating driver for AMLX [#8-K-2026-03-24] [#10-K-2026-03-03].
2026-12-31catalystAdditional pipeline execution updates beyond avexitideHigh impact
Amylyx's March 2026 8-K presentation also highlighted completed enrollment for Cohort 2 of the Phase 1 LUMINA trial and said AMX0035 in Wolfram syndrome is pending FDA alignment for a focused pivotal Phase 3 plan, giving the stock secondary execution checkpoints even before the main Phase 3 avexitide readout [#8-K-2026-03-24].
2028-01-01catalystCash runway supports pipeline into 2028High impact
The 10-K states AMLX had $317.0 million of cash, cash equivalents and marketable securities at December 31, 2025 and believes that cash funds operations into 2028, which lowers near-term financing pressure while multiple clinical programs mature [#10-K-2026-03-03].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-29 • Updated nightlySource: Internal modelMethodology